• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

健康成年人中的他汀类药物:一项荟萃分析。

Statins in Healthy Adults: A Meta-Analysis.

机构信息

Institute of Applied Health Sciences, School of Medicine, Medical Sciences and Nutrition, Epidemiology Group, University of Aberdeen, Aberdeen AB25 2ZD, UK.

出版信息

Medicina (Kaunas). 2021 Jun 7;57(6):585. doi: 10.3390/medicina57060585.

DOI:10.3390/medicina57060585
PMID:34200448
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8312228/
Abstract

: In this paper, we investigated the efficacy of statin therapy on cardiovascular disease (CVD) reduction in adults with no known underlying health conditions by undertaking a meta-analysis and systematic review of the current evidence. : We performed a systematic search to identify Primary Prevention Randomized Controlled Trials (RCTs) that compared statins with a control group where CVD events or mortality were the primary end point. Identified RCTs were evaluated and classified into categories depending on relevance in order to determine which type of meta-analysis would be feasible. : No differences were observed between categories with the exception of relative risk for all CVD events combined which showed a 12% statistically significant difference favouring studies which were known to include participants without underlying health conditions. Strong negative correlations between number-need-to-treat (NNT) and LDL-C reduction were observed for all Coronary Heart Disease (CHD) outcomes combined and all CVD outcomes combined. : This project highlights the need for further research on the effects of statins on participants who do not suffer from underlying health conditions, given that no such studies have been conducted.

摘要

: 在这项研究中,我们通过对现有证据进行荟萃分析和系统评价,研究了他汀类药物治疗对无潜在健康状况的成年人心血管疾病(CVD)减少的效果。: 我们进行了系统搜索,以确定将他汀类药物与以 CVD 事件或死亡率为主要终点的对照组进行比较的一级预防随机对照试验(RCT)。评估了确定的 RCT 并根据相关性进行分类,以确定哪种类型的荟萃分析是可行的。: 除了所有 CVD 事件的相对风险显示出统计学上有 12%的显著差异,有利于已知包括无潜在健康状况的参与者的研究外,类别之间没有观察到差异。所有冠心病(CHD)结局和所有 CVD 结局的联合观察到,数量需要治疗(NNT)和 LDL-C 降低之间存在强烈的负相关。: 鉴于没有进行此类研究,本项目强调了需要进一步研究他汀类药物对无潜在健康状况的参与者的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b755/8312228/394f2627fb9c/medicina-57-00585-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b755/8312228/900d95af2720/medicina-57-00585-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b755/8312228/ba75fd95f57a/medicina-57-00585-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b755/8312228/188bc4d44511/medicina-57-00585-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b755/8312228/394f2627fb9c/medicina-57-00585-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b755/8312228/900d95af2720/medicina-57-00585-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b755/8312228/ba75fd95f57a/medicina-57-00585-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b755/8312228/188bc4d44511/medicina-57-00585-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b755/8312228/394f2627fb9c/medicina-57-00585-g009.jpg

相似文献

1
Statins in Healthy Adults: A Meta-Analysis.健康成年人中的他汀类药物:一项荟萃分析。
Medicina (Kaunas). 2021 Jun 7;57(6):585. doi: 10.3390/medicina57060585.
2
A systematic review and economic evaluation of statins for the prevention of coronary events.他汀类药物预防冠状动脉事件的系统评价与经济学评估
Health Technol Assess. 2007 Apr;11(14):1-160, iii-iv. doi: 10.3310/hta11140.
3
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis.用于非透析慢性肾病患者的HMG辅酶A还原酶抑制剂(他汀类药物)
Cochrane Database Syst Rev. 2014 May 31(5):CD007784. doi: 10.1002/14651858.CD007784.pub2.
4
HMG CoA reductase inhibitors (statins) for kidney transplant recipients.肾移植受者使用的HMG CoA还原酶抑制剂(他汀类药物)
Cochrane Database Syst Rev. 2014 Jan 28;2014(1):CD005019. doi: 10.1002/14651858.CD005019.pub4.
5
Use of statins in primary and secondary prevention of coronary heart disease and ischemic stroke. Meta-analysis of randomized trials.他汀类药物在冠心病和缺血性中风一级及二级预防中的应用。随机试验的荟萃分析。
Int J Clin Pharmacol Ther. 2003 Dec;41(12):567-77. doi: 10.5414/cpp41567.
6
Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials.他汀类药物在主要冠脉事件和全因死亡率的一级和二级预防中的比较获益:基于安慰剂对照和阳性药物对照试验的网络荟萃分析。
Eur J Prev Cardiol. 2013 Aug;20(4):641-57. doi: 10.1177/2047487313480435. Epub 2013 Feb 27.
7
Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.用于成年人心血管疾病一级预防的他汀类药物:美国预防服务工作组的更新证据报告和系统评价。
JAMA. 2022 Aug 23;328(8):754-771. doi: 10.1001/jama.2022.12138.
8
Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.他汀类药物用于成人心血管疾病预防:美国预防服务工作组的证据报告和系统评价
JAMA. 2016 Nov 15;316(19):2008-2024. doi: 10.1001/jama.2015.15629.
9
Association of statin use in older people primary prevention group with risk of cardiovascular events and mortality: a systematic review and meta-analysis of observational studies.老年人初级预防组使用他汀类药物与心血管事件和死亡率风险的关系:观察性研究的系统评价和荟萃分析。
BMC Med. 2021 Jun 22;19(1):139. doi: 10.1186/s12916-021-02009-1.
10
Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials.他汀类药物治疗对心血管疾病的一级预防:随机对照试验的荟萃分析
Arch Intern Med. 2006 Nov 27;166(21):2307-13. doi: 10.1001/archinte.166.21.2307.

引用本文的文献

1
Short-Term Atorvastatin Therapy in Healthy Individuals Results in Unaltered Plasma MMP Levels and Disrupted MMP-7 Correlation with Blood Lipids and Blood Count-Derived Inflammatory Markers.健康个体短期阿托伐他汀治疗导致血浆基质金属蛋白酶水平未改变,且基质金属蛋白酶-7与血脂及血细胞计数衍生的炎症标志物之间的相关性被破坏。
J Clin Med. 2024 Aug 13;13(16):4743. doi: 10.3390/jcm13164743.
2
Lipid-lowering therapies for cardiovascular disease prevention and management in primary care: PEER umbrella systematic review of systematic reviews.初级保健中用于心血管疾病预防和管理的降脂治疗:PEER 伞式系统评价系统评价。
Can Fam Physician. 2023 Oct;69(10):701-711. doi: 10.46747/cfp.6910701.

本文引用的文献

1
LDL-C does not cause cardiovascular disease: a comprehensive review of the current literature.LDL-C 不会导致心血管疾病:对当前文献的综合综述。
Expert Rev Clin Pharmacol. 2018 Oct;11(10):959-970. doi: 10.1080/17512433.2018.1519391. Epub 2018 Oct 11.
2
Linking Chronic Inflammation with Cardiovascular Disease: From Normal Aging to the Metabolic Syndrome.将慢性炎症与心血管疾病相联系:从正常衰老到代谢综合征
J Nat Sci. 2017 Apr;3(4).
3
Small Dense Low-Density Lipoprotein as Biomarker for Atherosclerotic Diseases.小而密低密度脂蛋白作为动脉粥样硬化疾病的生物标志物
Oxid Med Cell Longev. 2017;2017:1273042. doi: 10.1155/2017/1273042. Epub 2017 May 7.
4
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.低密度脂蛋白导致动脉粥样硬化性心血管疾病。1. 来自遗传、流行病学和临床研究的证据。欧洲动脉粥样硬化学会共识小组的共识声明。
Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144.
5
Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?靶向炎症以降低心血管疾病风险:现实的临床前景?
Br J Pharmacol. 2017 Nov;174(22):3898-3913. doi: 10.1111/bph.13818. Epub 2017 Jun 10.
6
Relative risk versus absolute risk: one cannot be interpreted without the other.相对风险与绝对风险:两者不可分割。
Nephrol Dial Transplant. 2017 Apr 1;32(suppl_2):ii13-ii18. doi: 10.1093/ndt/gfw465.
7
Industry sponsorship and research outcome.行业赞助与研究成果。
Cochrane Database Syst Rev. 2017 Feb 16;2(2):MR000033. doi: 10.1002/14651858.MR000033.pub3.
8
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis.不同治疗干预措施下降低低密度脂蛋白胆固醇(LDL-C)与心血管风险降低之间的关联:一项系统评价和荟萃分析
JAMA. 2016 Sep 27;316(12):1289-97. doi: 10.1001/jama.2016.13985.
9
Interpretation of the evidence for the efficacy and safety of statin therapy.他汀类药物治疗疗效和安全性证据解读。
Lancet. 2016 Nov 19;388(10059):2532-2561. doi: 10.1016/S0140-6736(16)31357-5. Epub 2016 Sep 8.
10
Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease.在无心血管疾病的中危人群中降低胆固醇。
N Engl J Med. 2016 May 26;374(21):2021-31. doi: 10.1056/NEJMoa1600176. Epub 2016 Apr 2.